KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Parathyroid Hormone Modifies the Effect of Vitamin D Supplementation on Risk of Relapse or Death in Patients with Digestive Tract Cancer: A Post Hoc Subgroup Analysis of the AMATERASU Randomized Clinical Trial. PMID 42352547 · Cancers (Basel) · 2026-Jun-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy? PMID 42333037 · Head Neck · 2026-Jun-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials. PMID 41448868 · Br J Ophthalmol · 2026-Jun-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. PMID 42323390 · Prostate Cancer Prostatic Dis · 2026-Jun-20 The report is a subgroup analysis (Black patients) from a Phase III randomized trial (ARANOTE) with a time-to-event endpoint (rPFS) and a drug intervention (darolutamide). However, it is not an original formal result report of the primary trial population; it is a pre-specified subgroup analysis.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. PMID 42323161 · Ann Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium. PMID 42321916 · Trials · 2026-Jun-20 The record describes the design of a complex clinical trial (CHIP-AML22) but is a protocol paper, not an original report of formal results. While it includes randomized comparisons and time-to-event endpoints, the Phase III status is not explicitly confirmed in the provided metadata, and the report type is 'protocol' which is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. PMID 42259343 · Lancet · 2026-Jun-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. PMID 42259337 · Lancet · 2026-Jun-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). PMID 42096662 · J Clin Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Metformin enhances the pathological response in nondiabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: A randomized controlled trial. PMID 42456199 · J Pharmacol Exp Ther · 2026-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial. PMID 42330568 · Eur J Cancer · 2026-Jun-19 The record describes a school-based smoking prevention trial, not a human malignant-neoplasm trial. It does not involve a drug-containing intervention or a time-to-event oncology efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA. PMID 42319705 · Ther Innov Regul Sci · 2026-Jun-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema. PMID 42319677 · J Patient Rep Outcomes · 2026-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial. PMID 42319531 · Qual Life Res · 2026-Jun-19 The record is an original secondary analysis of a randomized trial, focusing on the prognostic association between patient-reported outcomes and overall survival. It is not the primary or key secondary report of the trial's efficacy results. The phase of the trial is not explicitly stated in the provided metadata, requiring manual review for phase confirmation. The report does not meet the strict criterion of being the primary formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized controlled trial comparing the effect of salivary substitute and fluoride varnish on radiation caries in irradiated head and neck cancer patients. PMID 42319482 · Support Care Cancer · 2026-Jun-19 The study is a randomized trial in human head and neck cancer patients, but it evaluates preventive dental interventions (salivary substitute, fluoride varnish) for radiation caries, not a drug-containing intervention for cancer treatment. The primary endpoint is DMFS score, a measure of dental decay, not a time-to-event efficacy endpoint. No Phase III/IIIb or Phase II/III designation is provided.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence. PMID 42352517 · Cancers (Basel) · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15-35 Years. PMID 42347661 · Vaccines (Basel) · 2026-Jun-18 The study is a Phase III randomized trial of an HPV vaccine (drug intervention) in humans with an oncology context (cancer prevention), but the primary endpoint is immunogenicity (GMT), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or analysis involving Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. PMID 42346269 · Curr Oncol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adverse events associated with immune checkpoint inhibitors in cervical cancer: A systematic review and meta-analysis of randomized controlled trials. PMID 42320227 · Eur J Obstet Gynecol Reprod Biol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer. PMID 42315785 · Pharmacoecon Open · 2026-Jun-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. PMID 42315278 · BMJ Open · 2026-Jun-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial. PMID 42313403 · JAMA Otolaryngol Head Neck Surg · 2026-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks. PMID 42313271 · Adv Ther · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. PMID 42150044 · N Engl J Med · 2026-Jun-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study. PMID 42107346 · Eur J Cancer · 2026-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial. PMID 41972998 · N Engl J Med · 2026-Jun-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prehospital Whole Blood in Traumatic Hemorrhage - A Randomized Controlled Trial. PMID 41841706 · N Engl J Med · 2026-Jun-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study. PMID 42310529 · J Headache Pain · 2026-Jun-17 The study is an open-label extension of a Phase 3 randomized trial, but it evaluates erenumab for chronic migraine, which is not an oncology indication. Therefore, it fails the core oncology criterion. Furthermore, the primary outcomes reported are safety and clinical global impression scores, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial. PMID 42310313 · Nat Commun · 2026-Jun-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5 Years of Experience with Fremanezumab: A Narrative Review. PMID 42310163 · Adv Ther · 2026-Jun-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Belimumab induces early and sustained resolution of lupus thrombocytopenia. PMID 42309555 · Lupus Sci Med · 2026-Jun-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. PMID 42309209 · Ann Oncol · 2026-Jun-17 The record is a human oncology, randomized trial with drug intervention and time-to-event efficacy endpoints (PFS, OS) reported as original results. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, keywords, publication type). The deterministic review flagged phase evidence as unclear. Therefore, the required criterion 'phase3_or_definitive' cannot be explicitly confirmed, making the study ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis. PMID 42308521 · Clin Exp Dermatol · 2026-Jun-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. PMID 42307914 · JAMA Cardiol · 2026-Jun-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis. PMID 42304472 · J Transl Med · 2026-Jun-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of PET-guided BrECADD with chemotherapy in advanced-stage, classical Hodgkin lymphoma. PMID 42304371 · Cost Eff Resour Alloc · 2026-Jun-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial. PMID 42303632 · Signal Transduct Target Ther · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series. PMID 42303407 · BMJ Open · 2026-Jun-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early Economic and Patient-Centered Outcomes Before Spine Metastases Radiation Therapy From an Ongoing Phase II Randomized Controlled Trial. PMID 42302152 · Am J Clin Oncol · 2026-Jun-16 This is an original report of an ongoing randomized phase II/III oncology trial (SPORTSMEN) comparing two radiotherapy regimens (SBRT vs. EBRT) for spinal metastases. However, it is a secondary analysis focusing on early economic and patient-reported outcomes (financial toxicity, quality of life), not a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The intervention is non-drug (radiotherapy only), so it fails the drug-intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Inpatient Metastatic Spine Score: Prospective Validation on an Ongoing Multicenter Phase II Randomized Controlled Trial. PMID 42302111 · Am J Clin Oncol · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo-Controlled, Phase III Trial. PMID 42299713 · Allergy · 2026-Jun-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. PMID 42299497 · Br J Haematol · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD. PMID 42298878 · Eur Psychiatry · 2026-Jun-16 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study. PMID 42298273 · Jpn J Ophthalmol · 2026-Jun-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study. PMID 42298272 · Jpn J Ophthalmol · 2026-Jun-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial. PMID 42261967 · J Am Heart Assoc · 2026-Jun-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. PMID 41953982 · Circulation · 2026-Jun-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy. PMID 41655979 · J Infect Dis · 2026-Jun-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Co-designing primary and secondary outcome measures for an international phase 3 trial of surgical de-escalation in vulvar cancer through a consumer workshop. PMID 42298648 · Res Involv Engagem · 2026-Jun-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. PMID 42298056 · Int J Clin Oncol · 2026-Jun-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -